about
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral loadResveratrol and Cardiovascular DiseasesReal time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort studyHigh-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic ratsCitrulline Supplementation Induces Changes in Body Composition and Limits Age-Related Metabolic Changes in Healthy Male Rats.Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease)Melatonin: action as antioxidant and potential applications in human disease and aging.[Ten-year morbidity and mortality in a cohort of dyslipidemic patients seen at a hospital endocrinology department].Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders.Glucose and reactive oxygen species.Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemiaThe role of antioxidant micronutrients in the prevention of diabetic complications.Diaphragmatic function is enhanced in fatty and diabetic fatty rats.Alterations in lipoprotein defense against oxidative stress in metabolic syndrome.Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and *NO bioavailability: Potential benefits to cardiovascular diseases.Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator.Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy.Hemolysis indexes for biochemical tests and immunoassays on Roche analyzers: determination of allowable interference limits according to different calculation methods.Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels.Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women.Piceatannol is more effective than resveratrol in restoring endothelial cell dimethylarginine dimethylaminohydrolase expression and activity after high-glucose oxidative stress.A perfusion bioreactor for engineering bone constructs: an in vitro and in vivo study.Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors.Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta.Modification of the β-Adrenoceptor Stimulation Pathway in Zucker Obese and Obese Diabetic Rat Myocardium.Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats.Hypoxia induces nitric oxide synthase in rheumatoid synoviocytes: consequences on NADPH oxidase regulation.Expression and extracellular release of Trx80, the truncated form of thioredoxin, by TNF-alpha- and IL-1beta-stimulated human synoviocytes from patients with rheumatoid arthritis.Implication of cytosolic phospholipase A2 (cPLA2) in the regulation of human synoviocyte NADPH oxidase (Nox2) activity.Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment.Interaction between non-anionic phospholipids and cytochrome c induced by reactive oxygen species.Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred.Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?Impaired glucose tolerance in patients with amyotrophic lateral sclerosis.Liquid chromatographic/electrospray ionization mass spectrometric identification of the oxidation end-products of trans-resveratrol in aqueous solutions.Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.Resveratrol opposite effects on rat tissue lipoperoxidation: pro-oxidant during day-time and antioxidant at night.
P50
Q21144283-81B5FC80-5D11-4789-9C62-BAAD33973AB1Q26752801-7BD86B47-DACF-4F09-9119-BE5169ED987DQ28482250-42912303-E170-4221-A61D-6A9CEA34F8F7Q28577216-DAF18D9D-E811-4BCD-93C4-8774A97C1E84Q30375060-29219B5F-9140-4BBA-93DE-E6780047386DQ30498009-252383B1-8733-4E07-83A2-FC4880BC2F2AQ34111973-89637333-FD23-443C-9AAE-364C2B213491Q34722638-E457DD04-2837-4079-B378-47AFDB608FC8Q34778960-DA3F0BF2-75D7-4ED6-9F0E-365C744917F9Q34781552-E6B204FC-DC67-4EE2-95D0-4ABB71EE7378Q35839693-F119296D-28D6-44F4-9BAF-B7536B3DFC4CQ36059957-5928E8CB-0B88-4BCF-B94D-2FBA83918312Q36318460-39344497-B897-464F-B5A6-173C412006D2Q36625116-03036C2B-12D1-40BE-80E8-9EF1B123DFC6Q36802138-B3E9B934-08EC-43E4-8B26-FA114C87DF37Q37963610-78D6D832-E37E-48E0-AC0F-0899E7017013Q38220707-6E778344-34F9-4FE5-93F2-141968330F0AQ38670035-F45632C0-91F1-4824-A874-00F060AF5576Q39052053-93DA807A-AE21-4636-A412-050151A8AB16Q39201137-DC70BAC8-E4AD-469A-84DD-D64B042E3BBEQ39294940-BE5708A9-DDAF-4ECA-B846-A232FD0237FEQ39607909-BD26B0FF-67B2-4CB6-9A56-995CA7FB86ACQ39617955-7B152E31-C646-446C-8805-49B0683084A5Q40153908-E6E9DE9F-E792-4FFE-898F-FAC649D63471Q40360872-CAEBBAB1-3837-4FCC-955E-FEFB64427EB3Q40397304-45E78A56-D716-4508-AA7C-ABAEBDCC05EFQ40727096-42B8DC3F-9926-4110-B360-C2AE03A22B07Q40831400-7BF5C1B6-F9DD-4BEA-A8BB-A2BF613ED5B5Q42109164-546D66E0-FEA0-4B37-A537-CDD5D72656E5Q42502040-B67EBEDF-973E-4B1D-9A44-D0B80A78ACADQ42511441-69E69A62-FADB-45AD-91F0-0028C82B0537Q42518854-272C7C28-2320-4D4A-A7DB-8957CA443051Q42748597-B3B50DC1-1C22-4810-AC83-5396C64F6334Q43096155-2B29BF9D-F99D-4C86-BB90-9BCF8E430E9EQ43102545-D2BE1175-91D6-4D41-876E-8A310E4DADB5Q43125205-03108D14-C24D-4C70-9546-D3C9377BD5A9Q43149662-D5C0D069-1656-40F5-9A59-B22D414DE4ACQ43162101-31827D93-7E4E-4FF0-9FDB-039544A92469Q43259468-4CB2F2CB-FA03-4417-99B8-2B803EF9C287Q43288954-78BADB6F-F7E4-4696-967B-82760D6F0C6D
P50
name
Dominique Bonnefont-Rousselot
@ast
Dominique Bonnefont-Rousselot
@en
Dominique Bonnefont-Rousselot
@es
Dominique Bonnefont-Rousselot
@nl
type
label
Dominique Bonnefont-Rousselot
@ast
Dominique Bonnefont-Rousselot
@en
Dominique Bonnefont-Rousselot
@es
Dominique Bonnefont-Rousselot
@nl
prefLabel
Dominique Bonnefont-Rousselot
@ast
Dominique Bonnefont-Rousselot
@en
Dominique Bonnefont-Rousselot
@es
Dominique Bonnefont-Rousselot
@nl